Pancreatic cancer remains one of the most formidable challenges in modern oncology, characterized by its aggressive nature and a tendency to spread silently long before a diagnosis is made. For many patients, the very first indication of the disease is not a localized pain in the abdomen, but rather symptoms arising from secondary tumors that have already taken root in distant organs. By the time these secondary growths—known as metastases—are detected, the primary cancer has typically reached a stage where it is notoriously difficult to control, often proving resistant to the standard battery of chemotherapy and radiation.
A breakthrough study led by scientists at the University of California, San Francisco (UCSF), published on May 21 in the journal Nature, has shed new light on how these cancer cells manage to colonize such diverse environments within the human body. The research identifies a specific protein, known as PCSK9, as a critical metabolic regulator that determines whether a migrating pancreatic cancer cell will thrive in the liver or the lungs. This discovery provides a detailed look at the "biological GPS" that pancreatic cancer uses to navigate and adapt to the vastly different chemical landscapes of the body’s internal organs.
To understand the significance of this finding, one must consider the monumental task a cancer cell faces when it leaves the pancreas. For a cell, moving from the pancreas to an organ like the liver or the lung is akin to a human traveler moving between an ocean and a desert. Each environment offers entirely different resources and presents unique hazards. The liver is a metabolic powerhouse, rich in nutrients and circulating fats, while the lungs are an oxygen-dense environment that, while vital for life, can be chemically hostile to a cell not properly equipped to handle high levels of oxidative stress.
The UCSF team, led by senior author Rushika Perera, PhD, the Deborah Cowan Endowed Associate Professor of Anatomy at UCSF, sought to understand the mechanisms that allow these cells to survive such drastic transitions. The researchers began their investigation by tapping into a massive repository of genomic and behavioral data known as MetMap. Developed by the Broad Institute, an independent research organization, MetMap is a comprehensive project designed to track and map the metastatic potential of hundreds of different cancer cell lines. By analyzing this data, the UCSF researchers were able to isolate specific pancreatic cancer cell lines that exhibited a distinct preference for colonizing either the liver or the lungs.
Once these cell lines were identified, the team performed a deep genomic analysis to determine what set them apart. They were looking for a molecular signature—a difference in gene expression or protein production—that could explain why one cell line would head for the liver while another would thrive in the lungs. Their search led them to PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). While PCSK9 is well-known in the medical community for its role in regulating blood cholesterol levels—and is the target of several modern heart disease medications—its role in the progression of pancreatic cancer had previously remained largely hidden.
